Clinical use of the fluoroquinolones

Medical Clinics of North America

Volumn 84, Issue 6, 2000, Pages 1447-1469

  Owens Jr , Robert C ^a,b   Ambrose, Paul G ^c,d  

^a MAINE MEDICAL CENTER   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c UNIVERSITY OF THE PACIFIC   (United States)

^d Princeton Corporate Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEPHALOSPORIN; CINOXACIN; CIPROFLOXACIN; CLINAFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ENOXACIN; FLEROXACIN; GATIFLOXACIN; GEMIFLOXACIN; GENTAMICIN; GREPAFLOXACIN; KANAMYCIN; LEVOFLOXACIN; LOMEFLOXACIN; MACROLIDE; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; OXOLINIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAPZID; SITAFLOXACIN; SPARFLOXACIN; TEMAFLOXACIN; TOBRAMYCIN; TOSUFLOXACIN; TROVAFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; CARDIOTOXICITY; CHONDROPATHY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; HEMOLYSIS; HUMAN; LIVER TOXICITY; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0033659828     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(05)70297-2     Document Type: Article

References (103)

1. Comparison of grepafloxacin with cefaclor in the treatment of community-acquired pneumonia
2. Early switch from intravenous to oral antibiotics in hospitalized patients with infections: A 6-month prospective study
3. Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites
4. Development of antibacterial agents of the nalidixic acid type
5. New antibiotics in pulmonary and critical care medicine: Focus on advanced generation quinolones and cephalosporins
6. New generation quinolones: With particular attention to levofloxacin
7. Antibiotic use in the critical care unit
8. Consequences of intravascular catheter sepsis
9. A randomized, prospective evaluation of an interventional program to discontinue intravenous antibiotics at two tertiary care teaching institutions
10. Tolerability of fluoroquinolone antibiotics: Past, present and future
11. Community-acquired pneumonia in adults: Guidelines for management
12. The triple threat of aspiration pneumonia
13. Temafloxacin syndrome: Review of 95 cases
14. Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin
15. Dose-ranging study of fleroxacin for treatment of uncomplicated Chlamydia trachomatis genital infections
16. Safety and tolerability of gatifloxacin, and advanced generation 8-methoxy fluoroquinolone
17. Antimicrobial switch therapy
18. Drug-resistant Streptococcus pneumoniae
19. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
20. Specific toxicologic aspects of the quinolones
21. Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia
22. Trovafloxacin adverse effects
23. Pharmacokinetic-pharmacodynamic contributions to the convulsant activity of fluoroquinolones in rats
24. Structure-activity and structure-side-effect relationships for the quinolone antibacterials
25. Effect of parenteral antibiotic administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract
26. Pharmacology of anti-infective agents
27. Torsades de pointe probably related to sparfloxacin
28. Intervention to discontinue parenteral antimicrobial therapy in patients hospitalized with pulmonary infections: Effect on shortening patient stay
29. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in the treatment of adults with community-acquired pneumonia
30. A prediction rule to identify low-risk patients with community-acquired pneumonia
31. A prospective, randomized, double-blind study treating community-acquired pneumonia in hospitalized patients: Gatifloxacin vs ceftriaxone/clarithromycin
32. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
33. Antibiotic optimization
34. Bactericidal activity of low-dose ceftizoxime plus metronidazole compared with cefoxitin and ampicillin-sulbactam
35. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy
36. Inappropriate use of oral ciprofloxacin
37. Ofloxacin versus parenteral therapy for chronic osteomyelitis
38. Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization
39. CID Hot Page
40. Superinfections with Streptococcus pneumoniae during therapy with ciprofloxacin
41. Time to clinical stability in patients hospitalized with community-acquired pneumonia: Implications for practice guidelines
42. Pharmacoeconomic benefit of antibiotic step-down therapy: Converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil
43. Streamlining antimicrobial therapy for lower respiratory tract infections
44. Fluoroquinolone antibacterial agents
45. Mechanisms of quinolone action and bacterial killing
46. Pharmacist-managed intravenous to oral step-down program
47. Rapid-growing mycobacteria
48. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy
49. Drug-induced pneumonitis with eosinophilic infiltration due to tosufloxacin tosilate
50. Fluoroquinolone antibacterials enhance UVA-induced skin tumors
51. Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa
52. Fluoroquinolone resistance in Streptococcus pneumoniae
53. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection
54. The effect of intravenous-to-oral switch guidelines on the use of parenteral antimicrobials in medical wards
55. Randomized, double-blind study of short-course (5 day) grepfloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis
56. Infectious complications with respiratory pathogens despite ciprofloxacin therapy
57. Fluoroquinolone toxicity profiles: A review focusing on newer agents
58. Safety profile of sparfloxacin, a new fluoroquinolone antibiotic
59. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae
60. Treatment of community-acquired pneumonia: A randomized comparison of sparfloxacin, amoxicillin-clavulanic acid and erythromycin
61. Oral ciprofloxacin for osteomyelitis
62. Infection due to infusion therapy
63. Fluoroquinolone phototoxicity: A comparison of moxifloxacin and lomefloxacin in normal volunteers
64. Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long wavelength UV light
65. Fulminant toxic epidermal necrolysis induced by trovafloxacin
66. Comparison of the bactericidal activity of trovafloxacin and ciprofloxacin, alone and in combination with cefepime, against Pseudomonas aeruginosa
67. Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents
68. Emergence of vancomycin tolerance in Streptococcus pneumoniae
69. Criteria-based antimicrobial IV to oral conversion program
70. Subtleties of quinolone safety and tolerability
71. Classifying quinolone anti-infective agents by generation: A pharmacodynamic approach to rational drug selection
72. In vitro synergistic activities of tobramycin and selected beta-lactams against 75 gram-negative clinical isolates
73. Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS
74. Review of structure-toxicity relationships of fluoroquinolones
75. Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy
76. Levofloxacin for drug-resistant Mycobacterium tuberculosis
77. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections: Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication
78. Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin
79. Single dose quinolone treatment in acute uncomplicated urinary tract infection in women
80. Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization
81. A pharmacist-initiated program of intravenous to oral antibiotic conversion
82. Ceftizoxime/metronidazole replaces cefotetan for intra-abdominal infections
83. Cefotaxime plus metronidazole for intra-abdominal infection
84. Clinical role of fluoroquinolones in patients with respiratory tract infections
85. Treating community-acquired pneumonia with once-daily gatifloxacin vs twice-daily clarithromycin
86. Early switch from intravenous to oral antibiotics and early hospital discharge
87. Single-dose ciprofloxacin in the treatment of uncomplicated urinary tract infection in women
88. Infectious complications of indwelling vascular catheters
89. Pneumococcal meningitis during intravenous ciprofloxacin therapy
90. Single-dose compared with 3-day norfloxacin treatment of uncomplicated urinary tract infection in women
91. Quinolones
92. Safety of long-term therapy with ciprofloxacin: Data analysis of controlled clinical trials and review
93. Safety profile of the quinolones
94. Efficacy and toxicity of fleroxacin in the treatment of travelers' diarrhea
95. A double-blind, randomized study of safety and efficacy treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin
96. Comparison of the pharmacodynamic activity of cefotaxime plus metronidazole with cefoxitin and ampicillin plus sulbactam
97. Initial clinical experience with clinafloxacin in the treatment of serious infections
98. Quinolone photoallergy: Photosensitivity dermatitis induced by systemic administration of photohaptenic drugs
99. Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone
100. A new fluoroquinolone for community-acquired pneumonia
101. Development of an intravenous-to-oral route conversion program for antimicrobial therapy at a Canadian tertiary care health facility